-
ImmVira Partners with Merz Aesthetics to Develop Anti-Wrinkle Exosome Products
•
Shenzhen-based ImmVira’s exosomes-focused subsidiary has struck a partnership with US leading firm Merz Aesthetics. The collaboration is focused on the development of ImmVira’s engineered exosome anti-wrinkle products in the US and Canada. Partnership DetailsThe partnership aims to utilize ImmVira’s engineered exosome anti-wrinkle product as the core functional ingredient to upgrade…
-
ImmVira’s MVR-T3011 IV Achieves Positive Outcomes in US Phase I Clinical Study
•
Shenzhen-based biotechnology company ImmVira has announced the successful completion of Phase I clinical studies in the United States for its intravenous oncolytic virus product, MVR-T3011 IV. The trial, which focuses on late stage patients with various tumor types, yielded “exceptional” safety results and demonstrated initial efficacy for certain indicationsThe study…
-
OBiO Technology and ImmVira Partner on Oncolytic Virus Project for BLA Filing and Commercialization
•
OBiO Technology (Shanghai) Co., Ltd (SHA: 688238), a leading gene therapy specialist based in China, has entered into a partnership with fellow Chinese firm ImmVira. The collaboration pertains to the Biologics License Application (BLA) filing and the commercial industrialization of an oncolytic virus project. ImmVira, which is responsible for the…
-
ImmVira’s MVR-C5252 Receives NMPA Approval for Glioma Treatment Development
•
China-based biotechnology company ImmVira has received approval from the National Medical Products Administration (NMPA) for its potentially groundbreaking oncolytic virus product, MVR-C5252, which is under development to treat gliomas. This first-in-class product marks a significant step forward in the treatment of brain tumors. Global Context and PrecedenceIn June 2021, Japanese…
-
ImmVira’s MVR-T3011 IT Shows Efficacy in Melanoma Treatment
•
Shenzhen-based biopharma ImmVira has revealed that its first intra-tumoral injection oncolytic virus (OV) product, MVR-T3011 IT, has produced positive signs of efficacy as a treatment for melanoma in late-stage patients who have failed previous immunotherapy. In a Phase II clinical study conducted in China and the United States, monotherapy treatment…
-
ImmVira Secures Series C+ Financing to Advance Oncolytic Virus and Exosome Programs
•
China-based biotech ImmVira has successfully secured its Series C+ financing, entering into agreements with a first batch of investors, including China Merchants China Direct Investments Ltd, Wuzhong Biomedical Industry Development Fund, and Qiandao Fund. The proceeds will be used to advance clinical studies of three product pipelines in the US…
-
Immvira’s Oncolytic Virus MVR-C5252 Receives FDA Orphan Drug Designation for Glioma
•
Shenzhen-based Immvira Co., Ltd, a biotech company focused on oncolytic viruses, announced that it has received orphan drug designation (ODD) status from the US Food and Drug Administration (FDA) for its herpetic oncolytic virus MVR-C5252. The designation is for the drug’s use in treating malignant glioma. Drug DetailsMVR-C5252, developed in-house…
-
ImmVira Partners with China Resources Biopharmaceutical on Oncolytic Virus MVR-C5252 for Gliomas
•
China-based biotech company ImmVira has entered into an exclusive partnership with compatriot firm China Resources Biopharmaceutical Co., Ltd to jointly develop MVR-C5252, a potential first-in-class oncolytic virus product for the treatment of gliomas and other central nervous system (CNS) tumors. Product DetailsMVR-C5252, developed using ImmVira’s OvPENS drug development platform, has…
